Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4569032 | 1.00 | TLR4 (0.44) | TLR4TLR2SLC2A1AKT1CETP | |
| SCHEMBL18539791 | 1.00 | TLR4 (0.44) | TLR4TLR2SLC2A1AKT1CETP | |
| SCHEMBL18539790 | 1.00 | TLR4 (0.44) | TLR4TLR2SLC2A1AKT1CETP | |
| SCHEMBL18539789 | 1.00 | TLR4 (0.44) | TLR4TLR2SLC2A1AKT1CETP | |
| SCHEMBL18539786 | 0.99 | AKT1 (0.43) | TLR4TLR2SLC2A1AKT1CETP | |
| SCHEMBL18539781 | 0.99 | AKT1 (0.43) | TLR4TLR2SLC2A1AKT1CETP | |
| SCHEMBL13881677 | 0.88 | AKT1 (0.46) | TLR4TLR2SLC2A1AKT1CETP | |
| SCHEMBL18550898 | 0.88 | AKT1 (0.46) | TLR4TLR2SLC2A1AKT1CETP | |
| SCHEMBL18550939 | 0.88 | AKT1 (0.46) | TLR4TLR2SLC2A1AKT1CETP | |
| SCHEMBL13881631 | 0.88 | AKT1 (0.46) | TLR4TLR2SLC2A1AKT1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885SLC2A1 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.